PrednisoneRebound effect manifesting as worsening of COVID-19 following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1938卷 / 1期

关键词：

D O I：

10.1007/s40278-023-31244-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1103 / 1103

相关论文

共 50 条

[31] RivoceranibNeurotoxicity following an off-label use: case report
[J]. Reactions Weekly, 2018, 1702 (1) : 232 - 232
[32] AzacitidineDiarrhoea following off-label use: case report
[J]. Reactions Weekly, 2019, 1736 (1) : 48 - 48
[33] RisdiplamPneumonia following off-label use: case report
[J]. Reactions Weekly, 2023, 1950 (1) : 348 - 348
[34] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2019, 1744 (1) : 111 - 111
[35] TocilizumabNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2021, 1853 (1) : 446 - 446
[36] NivolumabPsoriasis following an off-label use: case report
[J]. Reactions Weekly, 2018, 1717 (1) : 214 - 214
[37] SunitinibCardiomyopathy following off-label use: case report
[J]. Reactions Weekly, 2023, 1971 (1) : 240 - 240
[38] GlibenclamideHypoglycaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1857 (1) : 162 - 162
[39] PrednisoloneInefficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1910 (1) : 405 - 405
[40] ClonazepamMisidentification following off-label use: case report
[J]. Reactions Weekly, 2022, 1926 (1) : 171 - 171

← 1 2 3 4 5 →